echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Express treatment of Alzheimer's disease, stem cell therapy shows positive potential

    Express treatment of Alzheimer's disease, stem cell therapy shows positive potential

    • Last Update: 2021-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ▎Editor of WuXi AppTec's content team recently, GABAeron announced active preclinical research data obtained from cell therapy for Alzheimer's disease based on induced pluripotent stem cells (iPSC)
    .

    These data demonstrate the potential of transplanting interneuron progenitor cells derived from human iPSC differentiation in the treatment of Alzheimer's disease and other neurological diseases with interneuron defects or deletions
    .

    Previous studies have shown that people carrying the APOE4 gene have a higher risk of Alzheimer's disease and an earlier age of onset.
    About 60-75% of Alzheimer's patients will express APOE4 protein in the brain

    .

    Dr.
    Huang Yadong, co-founder of GABAeron Science, discovered an important cause of Alzheimer's disease caused by APOE4: APOE4 can cause damage and loss of GABAergic interneurons in the hippocampus of the brain

    .

    The hippocampus is an important area responsible for our learning and memory, and GABAergic cells are essential for maintaining normal hippocampal activities
    .

    In this study, scientists first successfully induced human iPSCs carrying the APOE3 gene to differentiate into GABAergic interneuron progenitor cells.
    The resulting cells showed high viability, purity and powerful functions, and more than 90% were in the correct developmental lineage

    .

    The researchers then transplanted them into the hippocampus of mice (10 months old) carrying the APOE4 gene
    .

    Experimental results show that interneuron progenitor cells exhibit a strong survival rate and mature and differentiate into functional GABAergic interneurons
    .

    Seven months after transplantation, more than half of the surviving cells have migrated out of the local area, filled different sub-regions of the hippocampus, and successfully established connections with other existing neurons in the hippocampus
    .

    ▲The poster displayed by GABAeron (picture source: reference [1]) electrophysiological records showed that the hippocampus of mice carrying APOE4 was defective, which may be the basis of memory impairment related to Alzheimer's disease
    .

    After receiving approximately 120,000 APOE3-carrying interneuron progenitor cells for 7 months, the activity of the hippocampus of these mice improved to the level observed in healthy mice
    .

    "If we can replace the missing interneurons through cell therapy, we can restore normal hippocampal activity, thereby slowing or reversing many of the memory and cognitive impairments associated with Alzheimer's disease," Dr.
    Huang explained, "if This method is effective, and one treatment may have a long-lasting effect on the patient

    .

    " Dr.
    Sheng Ding, co-founder of GABAeron Science commented: "After reaching this critical milestone, GABAeron is more confident about future clinical trials in humans.
    Moving forward

    .

    We also plan to explore the effects of cell therapy on other neurological diseases with defective or missing interneurons
    .

    "Reference: [1] GABAeron Presents Promising Preclinical Data on Stem Cell-Based Therapy for Alzheimer's Disease.
    Retrieved October 30, 2021, from https:// -data-on-stem-cellbased-therapy-for-alzheimers-disease-301409130.
    html Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress

    .

    This article is for information exchange only, and the views in the article do not represent medicine Ming AppTec’s position does not mean that WuXi AppTec supports or opposes the opinions
    in the
    article .
    This article is not a treatment plan recommendation

    .

    If you need treatment plan guidance, please go to a regular hospital
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.